TMEM9

Across TCGA pan-cancer cohorts, TMEM9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM9 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM9 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where TMEM9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.113	0.961	.024	16	view →
HNSC	DFS	Median	All	1.000	0.892	.006	12	view →
LSCC	DFS	Median	III,IV	0.616	1.000	.008	10	view →
GBM	OS	Median	All	0.887	0.742	.012	6	view →
PDAC	OS	Quartile	All	0.146	0.927	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM9–CCRCC (DFS)

Open the CCRCC breakdown →